Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
How do you approach treating a patient with RA and cirrhosis who did not respond to csDMARDs?
Related Questions
What is the maximum dose of leucovorin that you use with methotrexate?
Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
When considering a biologic for seropositive RA after failure of methotrexate or triple therapy, do you consider using abatacept as a first line biologic or would prefer choosing TNFi?
What is your approach to differentiating and managing DMARD-induced nodulosis (induced by methotrexate or leflunomide for example) from "de novo" RA nodules in seropositive RA patients?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
